Journal
PHARMACEUTICALS
Volume 8, Issue 1, Pages 1-20Publisher
MDPI
DOI: 10.3390/ph8010001
Keywords
multiple myeloma; proteasome inhibitors; toxicity
Categories
Funding
- California Institute for Regenerative Medicine
Ask authors/readers for more resources
Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available